Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03516981
Title	A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Merck Sharp & Dohme LLC
Indications	lung non-small cell carcinoma
Therapies	MK-1308 + Pembrolizumab MK-4280 + Pembrolizumab Lenvatinib + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| POL \| ITA \| IRL \| GBR \| ESP \| CHE \| CAN \| AUS